Teva Launches First Inhalable Antipsychotic Drug in U.S.

Adasuve reduces agitation in adults with schizophrenia or bipolar I disorder.

Teva Pharmaceutical Industries is launching the first orally inhaled medicine for treating agitation associated with adult schizophrenia or bipolar I disorder in the United States, the company announced on Monday.